Physician profile
John Nguyen
NPI 1942452255
$3,340.27
in general payments reported to CMS, 2019-2025
25 companies · $598 in 2025
The $598 reported for 2025 was more than what 77% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $355 · 2020: $311 · 2021: $669 · 2022: $333 · 2023: $520 · 2024: $555 · 2025: $598.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,673.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,672.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,398.18 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Abbvie INC. | $367.44 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $320.31 | 2019-2025 | Airsupra |
| Lilly USA, LLC | $270.61 | 2019-2024 | Mounjaro |
| Mayne Pharma Commercial LLC | $254.04 | 2021-2025 | |
| Pfizer INC. | $127.25 | 2021-2024 | |
| Exact Sciences Corporation | $91.78 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Amgen INC. | $66.67 | 2019-2024 | Evenity, Prolia |
| Phathom Pharmaceuticals, INC. | $42.85 | 2024-2025 | Voquezna |
| Therapeuticsmd, INC. | $42.46 | 2019-2022 | |
| Myovant Sciences INC. | $40.44 | 2021-2022 | |
| Agile Therapeutics, INC. | $34.80 | 2023-2024 | Twirla |
| Bayer Healthcare Pharmaceuticals INC. | $32.74 | 2021-2025 | |
| Millicent US INC | $28.45 | 2020 | |
| Eisai INC. | $27.75 | 2021-2025 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $27.40 | 2019-2023 | Gardasil 9, Vaxneuvance |
| Shield Therapeutics INC | $22.80 | 2025 | |
| Duchesnay USA Incorporated | $21.82 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $21.44 | 2025 | Jardiance |
| Astellas Pharma US INC | $20.53 | 2025 | Veozah |
| Sumitomo Pharma America, INC. | $19.63 | 2025 | Gemtesa |
| Exeltis, USA INC. | $16.58 | 2024 | Slynd |
| Idorsia Pharmaceuticals US INC | $16.17 | 2024 | Quviviq |
| Amag Pharmaceuticals, INC. | $14.38 | 2019 | |
| Galderma Laboratories, L.P. | $13.75 | 2025 | Dysport |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Nguyen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.